The ESETT trial gave us a reminder that our secondary AEDs aren't very good.
The ESETT trial gave us a reminder that our secondary AEDs aren't very good. Your luck is as good as a coin flip. With that in mind, we always take patient-specific factors to minimize potential ADE, while maximizing the therapeutic effects of our agents. I've got a fourth secondary AED in mind; do you know what it is? For more PHARMFAX in the drug bank, follow me @pharmwyze on all social media platforms for daily drug knowledge from a pharmaceutical pharmacologist 🧠❤️🤖.
The ALL PHARMWYZE SOURCE
Www.pharmwyze.com
Follow me on @pharmwyze
Twitter | Facebook | TikTok | Instagram | Medium | Website
Comments